Impact of Major Bleeding on 30-Day Mortality and Clinical Outcomes in Patients With Acute Coronary SyndromesAn Analysis From the ACUITY Trial
Steven V. Manoukian, MD, FACC*,*,
Frederick Feit, MD, FACC ,
Roxana Mehran, MD, FACC ,
Michele D. Voeltz, MD*,
Ramin Ebrahimi, MD, FACC ,
Martial Hamon, MD||,
George D. Dangas, MD, PhD, FACC ,
A. Michael Lincoff, MD, FACC¶,
Harvey D. White, DSc, FACC#,
Jeffrey W. Moses, MD, FACC ,
Spencer B. King, III, MD, MACC**,
E. Magnus Ohman, MD, FACC and
Gregg W. Stone, MD, FACC
* Department of Medicine, Emory University School of Medicine, Atlanta, Georgia
** Fuqua Heart Center, Atlanta, Georgia
Department of Medicine, New York University School of Medicine, New York, New York
Department of Medicine, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
Department of Medicine, University of California Los Angeles, Los Angeles, California
|| Service des Maladies du C ur et des Vaisseaux, Centre Hospitalier Universitaire de Caen, Caen, France
¶ Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio
# Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
 Department of Medicine, Duke University School of Medicine, Durham, North Carolina.

View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Independent Predictors of Major Bleeding
*Anemia was defined as baseline hemoglobin <13 g/dl in men and <12 g/dl in women. Renal insufficiency was defined as a creatinine clearance <60 ml/min as calculated by the Cockcroft-Gault equation. Unfractionated heparin or enoxaparin. CI = confidence interval; GPI = glycoprotein IIb/IIIa inhibitor; OR = odds ratio; PCI = percutaneous coronary intervention.
|
|
|